Elucid Labs aims to democratize AI-powered point-of-care medicine by performing digital biopsy. Elucid is a MedTech startup building the world's first AI-powered computational imaging device that is capable of detection and diagnosis of various diseases without the need for invasive procedures for the purposes of diagnosis and treatment planning. Currently, Elucid is building the world’s first AI dermatology assistant (AIDA) system for providing clinical decision support as well as productivity tool to medical practitioners for early detection and non-invasive diagnosis of skin cancer and diseases. AIDA fuses our proprietary digital biopsy computational imager with an explainable deep learning engine to give clinicians new insights into skin diseases. AIDA's patent pending computational imaging technology probes the molecular makeup of the skin at different layers and produces a 4000-parameter unique fingerprint for the lesion. AIDA's proprietary deep learning technology translates this fingerprint into valuable clinical knowledge to assist physicians in making better, faster, and well-informed decisions regarding diagnosis and course of treatment.
Using Elucid’s in-vivo digital biopsy capability, detection and diagnosis of skin cancer can be performed in a matter of seconds at much earlier stages of development, in turn reducing the cost of treatment as well as significantly reducing the unnecessary medical procedures carried out every year, while improving patient experience and outcome. Elucid will enable individuals to proactively participate in preventative personalized healthcare.